<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-2">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Aptos;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:12.0pt;
font-family:"Aptos",sans-serif;
mso-ligatures:standardcontextual;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#467886;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Aptos",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
mso-fareast-language:EN-US;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 70.85pt 70.85pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="SL" link="#467886" vlink="#96607D" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:36.0pt;font-family:"Calibri",sans-serif;color:#105A97">VABILO</span></b><span style="mso-ligatures:none;mso-fareast-language:SL"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:14.0pt;font-family:"Calibri",sans-serif;color:#105A97">Nacionalni inštitut za biologijo Vas vabi, da se udeležite seminarja</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-top:12.0pt;text-align:center"><b><span style="font-size:20.0pt;font-family:"Calibri",sans-serif;color:#2A8C46;letter-spacing:.05pt">»Improving outcomes for children with relapse and refractory acute myeloid
leukemia«,</span></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:14.0pt;font-family:"Calibri",sans-serif;color:#105A97"><br>
ki ga bo predstavil</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:9.0pt;font-family:"Calibri",sans-serif;color:#105A97"> </span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<b><span style="font-size:20.0pt;font-family:"Calibri",sans-serif;color:#105A97">dr. Richard Aplenc, MD, PhD</span></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#105A97">Mai and Harry F. West Endowed Chair in Pediatric Research</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#105A97">Professor of Pediatrics and Epidemiology</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#105A97">AVP and Chief Clinical Research Officer</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#105A97">The Children’s Hospital of Philadelphia</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<span style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#105A97">Perelman School of Medicine at the University of Pennsylvania</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;text-autospace:none">
<b><span style="font-size:9.0pt;font-family:"Calibri",sans-serif;color:#105A97"> </span></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center;line-height:115%"><span style="font-size:16.0pt;line-height:115%;font-family:"Calibri",sans-serif;color:#2A8C46;letter-spacing:.05pt"><img width="158" height="167" style="width:1.6458in;height:1.7395in" id="Picture_x0020_1" src="cid:image001.jpg@01DB9259.3ED235F0"></span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-bottom:12.0pt;text-align:center">
<b><span style="font-family:"Calibri",sans-serif;color:#2A8C46;letter-spacing:.05pt">Seminar bo v ponedeljek, 17. marca 2025, ob 13. uri na Nacionalnem inštitutu za biologijo,</span></b><span style="font-family:"Calibri",sans-serif;color:#2A8C46;letter-spacing:.05pt">
<br>
</span><span style="font-family:"Calibri",sans-serif;color:#7F7F7F;letter-spacing:.05pt">Večna pot 121, 1000 Ljubljana, v veliki predavalnici v prvem nadstropju, glavni vhod C/D.</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-top:6.0pt;text-align:center"><b><u><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#636363">Abstract:</span></u></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center"><span lang="EN-US" style="font-size:10.0pt;font-family:"Calibri",sans-serif;color:#636363">Acute myeloid leukemia (AML) is the second most common pediatric leukemia (500 cases per year). Current
treatment regimens for AML push the limits of chemotherapy intensity but cure only 60% of children. Given the remarkable success of chimeric antigen receptor (CAR) therapies for acute lymphoblastic leukemia (ALL), we seek to develop CAR T-cell (CART) therapies
for children with AML. Although AML CAR therapies have a promising efficacy signal, these therapies have not yet replicated the remarkable response rates seen in children for relapsed B-ALL, where the response rate exceeds 80%. We are actively investigating
multiple strategies to improve AML CAR efficacy, including identifying novel targets uninvolved with normal hematopoiesis and Phase I clinical trials. We have developed a novel cell surface protein enrichment protocol and target discovery analytic pipeline
that integrates transcriptomic and proteomic data. We have applied this workflow in two independent sample sets and identified over two hundred novel potential AML CAR targets. Taken together, our sample sets comprise the largest proteogenomic target discovery
effort to date in pediatric or adult AML. Data analyses integrating transcriptomic and proteomic data identified over two hundred potential targets for pediatric AML CAR development. Notably, multiple targets were identified based on proteomic data and would
not be identifiable through standard transcriptomic discovery approaches. We are also conducting a Phase I clinical trial with an anti-CD123 CAR which has shown generally acceptable toxicities and an initial efficacy signal.</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#636363"> </span></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-right:3.25pt;text-align:center">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#4F6228">Vljudno vabljeni. Seminar bo potekal v angleškem jeziku.</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-right:3.25pt;text-align:center">
<span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#4F6228">Na seminar se je potrebno prijaviti
</span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333"><a href="https://docs.google.com/forms/d/e/1FAIpQLSfEwSm9ng9TBNi39EMcvFGuhHn4QTkg712BVKjMX4ouq7f_pA/viewform?usp=header"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#0563C1">preko
spletnega obrazca</span></a></span><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#4F6228">.</span><o:p></o:p></p>
<p class="MsoNormal" align="center" style="margin-right:3.25pt;text-align:center">
<b><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#333333"> </span></b><o:p></o:p></p>
<p class="MsoNormal" align="center" style="text-align:center"><span style="font-size:11.0pt;font-family:"Calibri",sans-serif;color:#636363">Dodatne informacije: doc. dr. Anže Smole,
</span><span style="font-size:11.0pt;font-family:"Calibri",sans-serif"><a href="mailto:anze.smole@nib.si"><span style="color:#0563C1">anze.smole@nib.si</span></a><span style="color:#636363">.</span></span><o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:black;mso-fareast-language:SL"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:black;mso-fareast-language:SL"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:black;mso-fareast-language:SL"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-fareast-language:SL"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-fareast-language:SL">Žiga Cerkvenik<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-fareast-language:SL">Odnosi z javnostmi in komuniciranje znanosti / Public Relations and Science Communication<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="mso-fareast-language:SL"><a href="http://www.nib.si/"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;text-decoration:none">Nacionalni inštitut za biologijo</span></a></span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;mso-fareast-language:SL">
/ </span><span style="mso-fareast-language:SL"><a href="http://www.nib.si/eng/"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;text-decoration:none">National Institute of Biology</span></a></span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;mso-fareast-language:SL"><br>
</span><span style="mso-fareast-language:SL"><a href="http://www.nib.si/oddelki/skupne-slube"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;text-decoration:none">Skupne službe</span></a></span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;mso-fareast-language:SL">
/ </span><span style="mso-fareast-language:SL"><a href="http://www.nib.si/eng/index.php/departments/skupne-slube"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;text-decoration:none">Corporate Services</span></a></span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;mso-fareast-language:SL"><br>
Večna pot 121, SI-1000 Ljubljana, Slovenia<br>
<br>
Phone: + 386 (0)59 232 728<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#105A97;mso-fareast-language:SL">Mobile: + 386 0(31) 614 003
<br>
E-mail:</span><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#1F497D;mso-fareast-language:SL">
</span><u><span style="font-size:10.0pt;font-family:"Arial",sans-serif;color:#0563C1;mso-fareast-language:SL"><a href="mailto:ziga.cerkvenik@nib.si%20 ">ziga.cerkvenik@nib.si </a></span></u><span style="font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-language:SL"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span lang="EN-US" style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-ligatures:none;mso-fareast-language:SL"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><i><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-fareast-language:SL">Ne glede na čas, ko sem vam poslal to sporočilo, ne pričakujem odgovora izven vašega delovnega časa.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#2A8C46;background:white;mso-fareast-language:SL">Regardless of the time I sent this email, please do not feel you have to react outside of your own working hours.</span></i><i><span style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-fareast-language:SL"><o:p></o:p></span></i></p>
<p class="MsoNormal"><b><span lang="EN-US" style="font-size:9.0pt;font-family:"Arial",sans-serif;color:#2A8C46;mso-ligatures:none;mso-fareast-language:SL"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-language:SL"><img border="0" width="447" height="229" style="width:4.6562in;height:2.3854in" id="_x0000_i1026" src="cid:image002.png@01DB9259.3ED235F0"></span><u><span style="font-size:11.0pt;font-family:"Arial",sans-serif;color:#0563C1;mso-ligatures:none;mso-fareast-language:SL"><o:p></o:p></span></u></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>